Referrals Clinical Trials Department Newsletter Additional Links
 Patient Care
 Neurosurgery Research
  (BTRC) Brain Tumor Research Center
  Aghi Laboratory
  Alvarez-Buylla Laboratory
  Bankiewicz Laboratory
  Berger Laboratory
  Bergers Laboratory
  Cha Laboratory
  Clinical Neuro-Oncology Research
  Costello Laboratory
  Gupta Laboratory
  Haas-Kogan Laboratory
  Hodgson Laboratory
  Kunwar Laboratory
  Lal Laboratory
  Parsa Laboratory
  Pieper Laboratory
  Weiss Laboratory
  Wiencke Laboratory
  Wrensch Epidemiology Group
  Program Project Grant
  SPORE Grant Projects
  PBTF Grant Projects
  PLGA Grant Projects
  (BASIC) Brain and Spinal Injury Center
  Cerebrovascular Research
  Epilepsy Research
  Movement Disorders Research
  Pain Research
  Pediatric Clinical Research
  Tissue Bank
  Research Core Facility
  Guidelines on Research Data and Reports
 General Information
 Administrative Resources
Home > Neurosurgery Research > BTRC > Kunwar Laboratory  
Kunwar Laboratory
Principal Investigator: Sandeep Kunwar MD
Current Research Project
Dr. Kunwar's clinical research includes the development and institution of novel surgical-based therapies for the treatment of malignant gliomas. These strategies utilize tumor-targeted cytocidal proteins delivered through direct intracerebral microinfusion (convection-enhanced delivery), which bypasses the blood-brain barrier. His group's initial preclinical toxicity and distribution studies of one such compound, TP38, in nonhuman primates led to IND approval for a phase 1 study. A similar drug, IL13-PE38, and TP38, which are in phase 1 clinical trials at UCSF, represent a completely new method of tumor therapy using molecular targeting of tumor cells with direct delivery into the brain. To date, the group has treated eight patients with high-grade malignant tumors by using this molecular and regional targeting system. Early results indicate this to be a safe and effective method for drug delivery with some initial promising results. In the laboratory, in conjunction with Krys Bankiweicz PhD, he is exploring the delivery of other antitumor agents including immunoliposomes (with Dr. John Park) and viral particles into the brain. Studies in rodents and nonhuman primate models are underway in the hope of expanding the ability to selectively target tumor cells and deliver antitumor agents to regions of normal brain infiltrated with tumor.
UCSF UCSF Medical Center UCSF School of Medicine